Doxylamine/pyridoxine (Cariban®). HTA ID: 23052

Assessment Status Rapid Review Complete
HTA ID 23052
Drug Doxylamine/pyridoxine
Brand Cariban®
Indication Doxylamine/pyridoxine (Cariban®) is indicated for the symptomatic treatment of nausea and vomiting during pregnancy in adults who do not respond to conservative management.
Assessment Process
Rapid review commissioned 11/08/2023
Rapid review completed 30/08/2023
Rapid review outcome A full HTA is not recommended. The NCPE recommends that doxylamine/pyridoxine (Cariban®) not be considered for reimbursement at the submitted price*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

The HSE has approved reimbursement. March 2024.